首页> 外文期刊>European review for medical and pharmacological sciences. >Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling
【24h】

Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling

机译:T2DM骨折患者的上调血清菌丝蛋白水平抑制骨形成/重塑生物标志物的表达通过拮抗WNT信号传导

获取原文
           

摘要

OBJECTIVE: Bone formation/remodeling-associated biomarkers, such as osteocalcin, amino pro-peptide of type 1 collagen (P1NP) and CrossLaps (CTX) have been deregulated in type 2 diabetes mellitus (T2DM) patients. In particular, the T2DM-associated sclerostin markedly inhibits the bone formation, suppresses the osteoblast activity and downregulates the bone turnover. PATIENTS AND METHODS: In the present study, we examined the serum levels of sclerostin, osteocalcin, P1NP and CTX in the T2DM patients. We evaluated the regulation on osteocalcin, P1NP and CTX by sclerostin treatment in osteoblast hFOB 1.19 cells. Finally, we determined the mediation of Wnt signaling in the regulation by sclerostin on osteocalcin, P1NP and CTX in human osteoblast hFOB 1.19 cells. RESULTS: It was demonstrated that osteocalcin, P1NP and CTX were downregulated in the femur fracture of patients with T2DM, whereas the serum level of the sclerostin was markedly higher in the femur fracture of patients with T2DM. Moreover, the downregulated osteocalcin, P1NP or CTX was negatively associated with the upregulated sclerostin. In vitro results confirmed that sclerostin downregulated the expression of osteocalcin, P1NP and CTX in hFOB 1.19 cells. Also, our results demonstrated that Wnt/β-catenin inhibition was associated with the sclerostin-mediated inhibition of osteocalcin, P1NP and CTX in hFOB 1.19 cells. The Wnt/β-catenin level was markedly inhibited by sclerostin treatment, and the siRNA-mediated downregulation of β-catenin reduced the levels of osteocalcin, P1NP and CTX. CONCLUSIONS: Our study demonstrated that the upregulated serum sclerostin level in the T2DM patients with fracture inhibited the expression of the bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling. It suggests that sclerostin might be an effective target for T2DM-associated bone fracture and delayed fracture healing.
机译:目的:骨形成/重塑相关的生物标志物,如骨癌,1型胶原蛋白(P1NP)和交联剂(CTX)的氨基促肽已在2型糖尿病(T2DM)患者中进行了管制。特别地,T2DM相关的硬化蛋白显着抑制骨形成,抑制成骨细胞活性并下调骨质周转。患者和方法:在本研究中,我们检查了T2DM患者中血清菌丝,骨钙素,P1NP和CTX的血清水平。我们通过溶骨细胞HFOB 1.19细胞中的硬化素治疗评估了对Osteocalcin,P1NP和CTX的调节。最后,我们确定了在人骨液细胞中的骨钙素,P1NP和CTX调节中的WNT信号传导中的调解。结果:据证明,在T2DM患者的股骨骨折中下调骨钙,P1NP和CTX,而T2DM患者的股骨骨折明显较高。此外,下调的骨钙蛋白,P1NP或CTX与上调的硬化剂呈负相关。体外结果证实,硬化蛋白在HFOB 1.19细胞中下调了骨钙素,P1NP和CTX的表达。此外,我们的结果表明,Wnt /β-连环蛋白抑制与HFOB 1.19细胞中的骨钙蛋白,P1NP和CTX的溶质蛋白介导的抑制有关。通过硬化素治疗显着抑制Wnt /β-catenin水平,β-catenin的siRNA介导的下调降低了骨钙素,P1NP和CTX的水平。结论:我们的研究表明,T2DM骨折患者的上调血清菌丝蛋白水平抑制了通过拮抗WNT信号传导的骨形成/重塑相关生物标志物的表达。它表明,硬化素可能是T2DM相关骨折和延迟骨折愈合的有效靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号